roxithromycin-hexal 150 mg tablets
hexal pharma (sa) (pty) ltd - roxithromycin - tablets - roxithromycin tablets 150mg
tirabicin tablet, film coated 150mg
kleva s.a. 189 parnithos avenue, 13671 acharnai, attiki, greece - roxithromycin - film-coated tablet - roxithromycin 150 mg - antibacterials for systemic use
rulid 150 mg
sanofi - aventis israel ltd - roxithromycin - film coated tablets - roxithromycin 150 mg - roxithromycin - for the treatment of infections caused by microorganisms sensitive to roxithromycin e.g: ent bronchopulmonary, genital and skin manifestations.
apo-roxithromycin
apotex pty ltd - roxithromycin -
chemmart roxithromycin
apotex pty ltd - roxithromycin -
terry white chemists roxithromycin
apotex pty ltd - roxithromycin -
rulide roxithromycin 300mg tablet blister pack
sanofi-aventis australia pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: purified talc; hyprolose; propylene glycol; maize starch; magnesium stearate; povidone; glucose; poloxamer; titanium dioxide; hypromellose; colloidal anhydrous silica - for the treatment of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: . acute pharyngitis, tonsillitis, sinusitis; . acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia; . skin and skin structure infections; . non-gonoccocal urethritis. appropriate culture and sensitivity tests should be performed when necessary to determine organisms' susceptibility and thus treatment suitability. therapy with rulide may be initiated before results of these tests are known; once results become available, appropriate therapy should be considered.
rulide roxithromycin 150mg tablet blister pack
sanofi-aventis australia pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; purified talc; magnesium stearate; glucose; titanium dioxide; maize starch; povidone; poloxamer; propylene glycol; hypromellose - adults: for the treatment of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms in: acute pharyngitis; tonsillitis and sinusitis. acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia (including atypical pneumonia). skin and soft tissue infections and non-gonococcal urethritis children: for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis; acute tonsillitis; impetigo.
biaxsig roxithromycin 150mg tablet blister pack
sanofi-aventis australia pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: hypromellose; colloidal anhydrous silica; glucose; poloxamer; povidone; maize starch; purified talc; titanium dioxide; magnesium stearate; hyprolose; propylene glycol - for the treatment of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms in; acute pharyngitis, tonsillitis, and sinusitis. acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia (including atypical pneumonia). skin and soft tissue infections and non-gonococcal urethritis
roxithromycin tablets 150 mg bulk
alphapharm pty ltd - roxithromycin -